Can 4DMedical Sustain Momentum Beyond Early US Clinical Launches?
4DMedical secures a key clinical adoption milestone as the University of Miami begins using its CT – VQ™ respiratory imaging technology, following Stanford’s lead. Meanwhile, Lahey Hospital inks a two-year deal for IQ-UIP™, underscoring growing traction in US academic medical centers.
- University of Miami starts clinical use of CT – VQ™ with introductory pricing
- Second US academic medical center after Stanford to adopt CT, VQ™
- Two-year IQ-UIP™ agreement signed with Lahey Hospital & Medical Center
- Strong clinician engagement at RSNA conference fuels momentum
- 4DMedical’s SaaS model integrates advanced lung imaging into hospital workflows
Clinical Adoption Accelerates at Leading US Centers
4DMedical Limited (ASX, 4DX) has marked a significant commercial milestone with the University of Miami commencing clinical use of its CT, VQ™ respiratory imaging technology. This adoption follows closely on the heels of Stanford University’s recent launch, positioning 4DMedical’s solution as a rising standard in advanced lung imaging within top-tier academic medical centers (AMCs) across the United States.
The University of Miami’s pulmonary medicine program, nationally recognized for its expertise, is now integrating CT, VQ™ under a structured launch framework that includes a three-month introductory pricing period. This approach aims to ease early clinical adoption and workflow integration before transitioning to full commercial terms, reflecting 4DMedical’s strategic emphasis on building sustainable clinical partnerships.
Momentum Fueled by RSNA Engagement and Strategic Partnerships
The commercial launch at the University of Miami follows a period of intense clinician interest generated at the Radiological Society of North America (RSNA) conference. There, 4DMedical, in collaboration with Philips, hosted a well-attended breakfast event featuring expert panels that highlighted real-world applications of CT, VQ™. Discussions focused on how functional lung maps derived from the technology are enhancing clinical decision-making in screening, triage, and therapy planning, ultimately advancing cardiopulmonary care quality and efficiency.
Such engagement underscores the growing recognition of CT, VQ™ as a contrast-free, high-resolution alternative to traditional nuclear medicine ventilation-perfusion scans, a shift that could reshape respiratory diagnostics.
Expanding Footprint with Lahey Hospital & Medical Center
Complementing this momentum, 4DMedical has secured a two-year agreement with Lahey Hospital & Medical Center, a leader in pulmonary medicine and interventional pulmonology. Lahey will deploy 4DMedical’s IQ-UIP™ software, which offers quantitative CT analysis for idiopathic pulmonary fibrosis and related interstitial lung diseases, under an annual subscription model with capacity for up to 24,000 scans.
This deal not only broadens 4DMedical’s presence in the US healthcare market but also highlights the company’s expanding portfolio of AI-driven respiratory imaging solutions delivered via a Software-as-a-Service (SaaS) model, facilitating seamless integration into existing hospital infrastructure.
Looking Ahead, Building a Network of Reference Sites
4DMedical’s CEO Andreas Fouras expressed enthusiasm about the rapid transition from RSNA engagement to commercial operations, emphasizing the company’s strategy to establish key US AMCs as reference sites for CT, VQ™. This network approach aims to drive broader adoption and validate the technology’s clinical and economic benefits across diverse healthcare settings.
As 4DMedical continues to push the boundaries of respiratory imaging with its patented XV Technology® and AI capabilities, the unfolding US commercial expansion will be a critical indicator of its long-term growth trajectory and impact on lung health diagnostics.
Bottom Line?
4DMedical’s swift US clinical adoption signals a pivotal step toward reshaping respiratory imaging standards nationwide.
Questions in the middle?
- How will the introductory pricing period at the University of Miami affect near-term revenue recognition?
- What are the prospects for CT – VQ™ adoption beyond early academic medical centers?
- How will integration of AI-driven imaging tools like IQ-UIP™ influence treatment outcomes for pulmonary diseases?
